LBH589 and Gemcitabine in the Treatment of Solid Tumors

NCT00550199 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Study terminated due to LBH589 toxicity.

Conditions

Solid Tumors

Interventions

DRUG: LBH589, Gemcitabine

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]